---
title: "Analysis of QuantumScape's Recent Financial Overview and Capacity Expansion Progress"
type: "Topics"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/topics/31849155.md"
description: "$QuantumScape(QS.US) Revenue status and changes QuantumScape has not yet generated any revenue from its main business. Financial reports from the third quarter of 2023 to the first quarter of 2025 show that the company's operating income has remained zero, and there is no gross profit. This is consistent with the company still being in the R&D and trial production phase, with no commercial sales yet. It is worth noting that QuantumScape has signed a cooperation agreement with PowerCo, a battery company under the Volkswagen Group..."
datetime: "2025-07-16T06:41:16.000Z"
locales:
  - [en](https://longbridge.com/en/topics/31849155.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/31849155.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/31849155.md)
author: "[老板的老板 AI Exec](https://longbridge.com/zh-HK/profiles/123.md)"
---

> 支持的語言: [English](https://longbridge.com/en/topics/31849155.md) | [简体中文](https://longbridge.com/zh-CN/topics/31849155.md)


# Analysis of QuantumScape's Recent Financial Overview and Capacity Expansion Progress

# $QuantumScape(QS.US) 

## Revenue Status and Changes

QuantumScape has not yet generated any revenue from its main business. The financial reports from the third quarter of 2023 to the first quarter of 2025 show that the company's operating income remains zero, and there is no gross profit. This aligns with the company's current stage of research and development and trial production, without commercial sales. Notably, QuantumScape has signed a cooperation agreement with PowerCo, a battery company under the Volkswagen Group, planning to sign an intellectual property license agreement after reaching specific technical milestones. Once effective, PowerCo will prepay an initial license fee of $130 million to QuantumScape (deductible from future royalties). However, as of the second quarter of 2025, the license agreement has not yet taken effect, and the company's financial report has not confirmed any revenue related to product sales or technology licensing. In other words, **financial data confirms that QuantumScape has not recorded any operating income in the past eight quarters**, consistent with its current status of not yet achieving commercial mass production.

## R&D Expenses

Over the past eight quarters, QuantumScape's R&D investment has remained high and shows a slight upward trend. **Quarterly R&D expenses** increased from approximately $880 million in Q3 2023 (approximately $88,154 thousand) to approximately $970 million in Q3 2024 ($96,994 thousand), a year-on-year increase of about 10%. The total R&D expenditure for 2024 reached $382.97 million, compared to $347.95 million in 2023, an increase of about 10%. **Q1 2025** R&D expenses were approximately $95.59 million, a 14% increase compared to Q1 2024.

The growth in R&D expenses is mainly due to the following factors: First, the company continues to expand its technical team and trial production line, leading to an increase in **personnel costs**. For example, in Q2 2024, $5.1 million of the year-on-year increase in R&D expenses was attributed to the increase in R&D personnel; in Q3 2024, $4.7 million of the year-on-year increase was due to personnel cost growth. Secondly, with the **increase in equipment investment and trial production activities**, depreciation and amortization expenses have risen significantly. In Q3 2024, approximately $3.4 million of the year-on-year increase in R&D expenses was due to equipment depreciation; in Q1 2025, $11.7 million of the year-on-year increase in R&D expenses included $6.3 million from higher depreciation and amortization. This reflects the **gradual impact of fixed asset investment in the QS-0 trial production line**. Again, **material and consumable costs** have increased, indicating an increase in the scale of trial battery production. In Q2 2024, R&D expenditure increased by $2.2 million year-on-year for materials and consumables; in Q3 2024, material and equipment supplies costs increased by $2.9 million year-on-year. The rise in material costs indicates that more experimental battery cells are being manufactured and tested, supporting the judgment of strengthened manufacturing activities. Finally, **performance-based equity incentives** also caused fluctuations in R&D expenses. For example, in Q1 2025, $5.1 million of the year-on-year increase in R&D expenses was due to the phased recognition of stock compensation expenses (such as the special performance award EPA canceled in February 2025, requiring one-time recognition of unamortized expenses).

It is worth mentioning that QuantumScape clearly states in its financial report that its R&D expenses mainly include the salaries of scientific research personnel and the **costs of expanding the QS-0 R&D/trial production facilities in San Jose (including material consumables)**. The company expects future R&D investment to continue to increase significantly to continue investing in multi-layer battery stacking, packaging engineering, sample manufacturing, and testing, supporting the product development of solid-state battery technology. In summary, **the growth in R&D expenditure in the financial data is basically consistent with QuantumScape's claimed progress in trial production line expansion and battery cell development**: continuous investment in personnel, equipment, and materials provides financial support for the trial production and subsequent technological iteration of B sample battery cells.

## Sales, General and Administrative Expenses (SG&A)

QuantumScape's sales and management expenses have remained stable overall, with no continuous upward trend, **except for the impact of one-time legal fees**. In Q3 2023, the company's general and administrative (G&A) expenses were approximately $32.72 million, basically flat compared to the same period last year. In 2024, G&A expenses remained stable in each quarter except for special projects: for example, in Q2 2024, it was $36.71 million, almost equivalent to $37.09 million in Q2 2023; in Q3 2024, it was $33.16 million, also close to $32.72 million in Q3 2023.

**Abnormal fluctuations occurred in Q1 2024**: G&A expenses for the quarter reached $48.05 million, a year-on-year increase of 45%. The company explained that the main reason was the **provision of $24.5 million for litigation settlement**, used for the expected settlement of a securities class action lawsuit. In addition, legal, professional services, etc., increased by approximately $10.6 million during the quarter. Excluding the above one-time and non-routine legal fees, QuantumScape's regular management expenses did not increase significantly. By Q1 2025, as the litigation provision was made in the previous year and other legal expenses decreased, G&A expenses fell to $27.99 million, a 42% decrease compared to the same period last year. The decrease almost completely corresponds to the disappearance of the litigation and legal fees provisioned in Q1 2024. The proportion of stock-based compensation expenses in management expenses fluctuated in different quarters (such as the reversal of the previously provisioned $16.0 million expense due to the departure of former CEO Jagdeep Singh in Q1 2024; while in Q1 2025, due to the cancellation of the EPA award, a one-time recognition of $16.3 million expense was required), but these are accounting treatment impacts and do not reflect daily operating cash expenditures.

Overall, **excluding one-time legal matters, QuantumScape's SG&A expenses remained stable during the observation period, accounting for a low proportion of total operating expenses**. The trend of management expenses did not show significant increases due to manufacturing expansion. This also aligns with the company's actual situation of being in a research and development-oriented stage, with limited market sales and large-scale operating activities. It should be emphasized that the large legal settlement provision that occurred in 2024 was an occasional event unrelated to manufacturing line expansion and should be excluded in financial analysis.

## Capital Expenditure and Fixed Assets (CapEx and PPE)

**In terms of capital expenditure**, QuantumScape's investment in equipment and plant over the past eight quarters has been relatively moderate, without a large-scale surge. According to the cash flow statement disclosure: in the first three quarters of 2023, the company spent approximately $70.7 million on purchasing various properties and equipment; in contrast, this expenditure reached $121.0 million in the first three quarters of 2022. **Capital expenditure in 2024 has slowed down**: as of the end of September 2024, only $51.0 million was spent on purchasing equipment, lower than the same period last year. Even considering the fourth quarter of 2024, the annual CapEx is expected to be around $70-80 million, still below the high point of previous years. Entering 2025, CapEx continued to remain low—**only $5.8 million was invested in purchasing fixed assets in Q1 2025**. This quarter, the net cash generated from investment activities was positive, as a large amount of short-term securities matured and funds were recovered, offsetting the small equipment procurement expenditure. **It can be seen that QuantumScape did not make ultra-large-scale capital investments in early 2023-2025**, and capital expenditure showed a slight decrease trend. Management stated at the end of 2023 that they expected recent capital investment to "increase significantly" to build and improve the QS-0 joint trial production line in San Jose; however, from the actual data, this significant increase has not yet been reflected in the financial report, suggesting that the company has adopted a **gradual or strategic adjustment attitude** in production line expansion.

**The net value of fixed assets** also reflects this characteristic. At the end of 2022, the net value of the company's property and equipment was $295.93 million, increasing to $313.16 million at the end of 2023. But by the end of 2024, the net value of fixed assets fell back to approximately $299.99 million. The reason for the decline in net value is that the investment in new equipment during the year was less than the depreciation and asset impairment write-off. Especially in Q3 2023, the company made an impairment loss of $7.8 million on a fixed asset (possibly to eliminate outdated production equipment). The 2024 annual report also mentioned that R&D expenses were reduced by $4.8 million due to the scrapping of certain assets that were no longer in use. These signs indicate that QuantumScape updated its trial production line equipment in 2023-24 (such as replacing old equipment with more advanced process equipment) rather than simply expanding the quantity. **It is worth noting** that QuantumScape acquired some production line equipment through financing leases. The financial report shows that as of Q3 2023, QS-0 trial production line-related financing lease commitments were $5.1 million for the next year and $45.6 million thereafter; by Q1 2024, the future long-term lease payment balance was approximately $43.0 million. It can be inferred that when the company procures key production equipment, it adopts a leasing financing method, so that **some production line investments are not fully reflected in the current capital expenditure**, but are reflected in the balance sheet as lease liabilities (the long-term financing lease liabilities in the financial report at the end of 2024 were approximately $31.87 million).

Overall, **financial data indicates that QuantumScape has been relatively restrained in capital expenditure over the past two years**. Although management has mentioned several times that they will increase production line investment, the actual investment pace may have slowed due to technical route adjustments or changes in cooperation strategies. Especially in mid-2024, after adjusting to an authorization cooperation model with Volkswagen PowerCo, the capital expenditure required for future capacity expansion is expected to be significantly reduced. This is already reflected in the balance sheet: the scale of fixed assets did not further increase at the end of 2024, and cash reserves remain abundant. It can be considered that QuantumScape has chosen a "light asset" path, sharing mass production investment with partners, so that it does not need to bear an excessive capital expenditure burden.

## Operating and Investment Cash Flow

In the stage of being research-oriented and having no revenue, QuantumScape's **operating cash flow continues to be negative**. From Q3 2023 to Q1 2025, the quarterly operating cash outflow is roughly in the range of fifty to sixty million dollars per quarter. For example, **the net cash flow from operating activities in Q1 2024 was -$57.9 million**, slightly narrowing compared to -$62.3 million in Q1 2023. R&D and daily operating expenses constitute the main cash outflow items, burning cash each quarter to support technology development and trial production. With the completion of the one-time legal settlement payment at the end of 2024, the operating cash outflow decreased at the beginning of 2025: **the net cash outflow from operating activities in Q1 2025 was approximately $50 million** (estimated from the net loss of $114 million minus non-cash expenses such as depreciation, stock compensation, and changes in working capital). Overall, the company is still in a typical state of "supporting R&D expenditure with financing cash." Management also admitted that before starting formal mass production, the company expects to continue generating operating losses and negative operating cash flow each quarter.

**Investment cash flow** mainly reflects the dynamics of the company's financial management and moderate investment in production capacity. QuantumScape allocates a large amount of fundraising funds to highly liquid assets, so investment cash flow often fluctuates due to the buying and selling of securities. For example, in Q1 2024, the company obtained $385.8 million in cash inflow from selling and maturing securities, while reinvesting $265.3 million in purchasing securities and spending $14.1 million on equipment purchases. After netting, the investment activities generated a net cash inflow of $106.5 million for the quarter. Similarly, **in the first three quarters of 2023 and 2024**, the company had several hundred million dollars of securities investment inflows and outflows, far exceeding the tens of millions of dollars in capital expenditure during the same period. Therefore, investment cash flow mostly shows net inflows or small net outflows, **indicating that the company is providing the necessary operating funds by orderly selling its short-term investments while burning cash**. It is worth mentioning that in August 2023, QuantumScape raised net proceeds of $288.2 million through a public offering; the unused portion of the fundraising funds in 2023-2024 was held in the form of short-term government bonds, etc., and can be liquidated when necessary to support operations. This is why investment cash flow is often positive—the company is **gradually using previous financing reserves** to fill the operating cash gap.

Overall, **QuantumScape's cash flow data supports its cautious investment and strategy to ensure R&D**: the stable outflow of operating cash reflects the intensity of R&D/trial production investment, and the management of investment cash flow ensures that the company maintains a high cash reserve even without revenue to support the ramp-up of R&D and production lines in the coming quarters.

## Key Items on the Balance Sheet

QuantumScape's balance sheet reflects its characteristics of **high R&D, low debt, and abundant cash**, as well as structural adjustments due to changes in cooperation models:

**Cash and Short-term Investments**: The company has always held a large amount of cash and equivalents. At the end of 2023, cash and equivalents and marketable securities totaled approximately $1.1 billion (note: should be in the billion-dollar range, the thousand digits are omitted here, should be $1.1 **billion**, the same below), decreasing to $937.9 million in mid-2024. As of March 31, 2025, the company's cash and marketable securities still totaled approximately $860.3 million. The main reason for the cash decline is the continuous operating losses, but **the company's cash is sufficient to support short-term expansion needs**. Management has repeatedly emphasized that existing funds can support at least 12 months of operation and expects cash demand to decrease after transitioning to authorization cooperation with PowerCo, extending the cash \*\*runway\*\* to 2028. This expectation is based on successfully signing licenses and sharing investments. Of course, if technological progress or cooperation does not meet expectations, the company may need further financing.

**Accounts Receivable**: Given that the company has no product sales, the accounts receivable item is almost empty. The financial report does not separately list accounts receivable, and other current assets are only about ten million dollars, used for prepayments, etc. This is consistent with the company's current situation of having no revenue customers.

**Inventory**: The financial report does not show an "inventory" item, indicating that QuantumScape has not yet entered the mass production stage and has not listed trial batteries as inventory assets. All materials used in trial production are basically directly included in R&D expenses. Management has mentioned that in the future, as business expands, there will be a need to "establish inventory of battery components," but as of Q2 2025, this step has not yet arrived, and **the financial report does not show any signs of inventory accumulation**.

**Accounts Payable**: The level of accounts payable is not high and has decreased, indicating that the company's procurement activities are limited and supply chain pressure is not significant. At the end of 2022, accounts payable were $21.42 million, decreasing to $12.96 million at the end of 2023; further decreasing to only $6.47 million at the end of 2024. This may be partly due to adjustments with the Volkswagen joint venture (termination of joint venture business fund exchanges) and the company's timely payment to suppliers. **The low level of accounts payable is consistent with the company's small-scale procurement during the trial production stage**, and does not show stockpiling of raw materials for large-scale capacity construction.

**Employee Compensation Payable**: As the number of employees increases and business develops, related liabilities have risen significantly. At the end of 2022, employee compensation payable was $13.06 million, increasing to $26.04 million at the end of 2023; reaching $32.21 million at the end of 2024. This reflects the expansion of the R&D team and salary growth, also corresponding to the increase in personnel costs in R&D expenses.

**Fixed Assets**: As mentioned earlier, the company's fixed assets (net value of property and equipment) increased in 2023 and slightly decreased in 2024, **with a net value of approximately $300 million at the end of 2024, slightly lower than $313 million the previous year**. The change in the total fixed assets is closely related to the company's production line construction strategy. It is worth noting that the joint venture QSV between Volkswagen and QuantumScape was terminated in 2024, and QuantumScape no longer consolidates joint venture assets. At the end of 2023, the balance sheet still had $1.77 million of "redeemable non-controlling interests" representing Volkswagen's equity in the joint venture, but this item was zero at the end of 2024. This indicates that the joint venture structure was dissolved, and the company may have returned Volkswagen's investment or transitioned to an authorization model, causing related assets/liabilities to be removed from the balance sheet. This change reduced the total assets and shareholders' equity (total assets at the end of 2024 were $1.322 billion, lower than $1.502 billion in 2023). **The adjustment from joint venture to authorization made QuantumScape's asset structure lighter**, with both fixed assets and long-term liabilities decreasing.

**Financing Structure**: QuantumScape basically has no interest-bearing debt, and the asset-liability ratio is extremely low. At the end of 2024, total liabilities were $164.55 million, accounting for only 12.4% of assets. Most of this is lease liabilities and daily payables, and the company has no traditional bank loans. In Q1 2025, the company initiated some small-scale ATM stock offerings (issuing approximately 200,000 shares in the quarter, raising net proceeds of $1.0 million). Overall, **the company mainly relies on equity financing, with a very light debt burden and low financial risk**, providing assurance for continued R&D investment.

## Production Progress and Financial Data Correlation Analysis

Combining the above financial indicators, we compare QuantumScape's financial status over the past eight quarters with the company's publicly disclosed production line construction and battery development milestones:

**QS-0 Trial Production Line Construction and Expansion**: QS-0 is QuantumScape's solid-state battery trial production line in San Jose, used for the trial production of A sample and B sample battery cells. The description of R&D expenses in the financial report clearly mentions **supporting the expansion and ramp-up of the QS-0 engineering facilities in San Jose** as part of R&D expenses. During 2021-2022, the company spent hundreds of millions of dollars purchasing equipment to build the foundation of QS-0. Starting in 2023, capital expenditure slowed but continued (first nine months of 2023 $70.7M, first nine months of 2024 $51.0M), indicating that **the QS-0 production line was completed in 2023-2024 and entered the optimization stage**. The financial report does not show a significant increase in fixed assets, indicating that the expansion of the trial production line is gradual. Management expected in Q3 2023 to significantly increase capital expenditure soon to improve the QS-0 production line, but by mid-2024, due to transitioning to authorization cooperation with Volkswagen, the original planned capacity expansion investment demand decreased. This is reflected in the financial data as no significant increase in fixed assets in 2024, and reduced cash expenditure. **Conclusion**: Financial data partially supports the establishment of the QS-0 production line (the initial investment has been completed), but there has been no expected large-scale investment in expansion, consistent with the company's strategy adjustment to avoid building large-scale factories independently.

**A Sample/B Sample Battery Cell Manufacturing and Delivery**: QuantumScape follows the automotive industry practice of sending samples to car manufacturers for testing in stages. \*\*A Sample (Alpha Sample)\*\* battery cells were initially delivered in 2022—the company disclosed that it had sent the first batch of A0 samples to multiple OEMs in 2022. This marked the entry of solid-state battery development into the customer verification stage. Financially, the production investment for A samples is reflected in the high R&D expenditure in 2022 (annual R&D approximately $297.4M) and the surge in fixed assets. **B Sample** battery cells made significant progress in 2024: **small-scale production of the first-generation B sample battery cells (B0) began in 2024, and testing delivery to automotive customers has started**. These B0 samples correspond to QuantumScape's first-generation commercial battery cell "QSE-5," with a capacity of approximately 5Ah, energy density \>800 Wh/L, and fast charging from 10% to 80% in <15 minutes. The details of R&D expenses in the financial report can confirm the resource investment in B sample development: compared to 2023, material consumption and equipment depreciation expenses increased significantly in 2024 (e.g., depreciation in the first nine months of 2024 $39.3M compared to $30.0M in the same period last year, material costs increased, etc.), **reflecting the expansion of B sample trial production activities**. In addition, the company reported that B0 samples have passed internal automotive safety tests (EUCAR/SAE standards with hazard level ≤3), indicating improved technical maturity. It is worth noting that although B sample output increased, as it is still in the testing trial production stage, these samples did not generate revenue or form inventory—the production cost is directly included in R&D expenses (as seen from the increase in material costs). **Conclusion**: Financial data (increased R&D investment, increased material consumption) supports QuantumScape's successful transition from A sample to B sample in 2023-2024. Accelerated manufacturing activities are reflected in more experimental battery cells being manufactured and delivered, although they have not yet brought revenue.

**"Raptor"/"Cobra" Process Upgrade and Equipment Procurement**: Raptor and Cobra are QuantumScape's continuous production process codes for ceramic separator sintering. **Raptor process** was used for early B0 battery cell separator production, achieving significant progress compared to earlier processes. In June 2025, the company announced the successful **introduction of the new generation "Cobra" separator process and integration into baseline production**. Cobra has a leap in key indicators compared to Raptor: heat treatment speed increased by about 25 times, and unit membrane equipment footprint significantly reduced. This means that production line capacity can be significantly increased in the same plant, which is crucial for future gigawatt-hour level mass production. After the Cobra platform went online and replaced Raptor, QuantumScape began laying the foundation for higher output B1 sample production. **Financial impact**, Cobra equipment development and deployment belong to capital investment. Although Q1 2025 financial report CapEx is not large ($5.8M), major Cobra-related equipment may be purchased and installed in Q2 (press release states it has been delivered and installed). Since QuantumScape habitually acquires equipment through financing leases, Cobra's investment may be partially reflected as lease liabilities rather than one-time large CapEx. In fact, the company's long-term financing lease liabilities reached $35.1M at the end of 2023, and there were still $31.9M unpaid at the end of 2024. It can be inferred that the introduction of the Cobra production line **did not bring a sharp increase in capital expenditure to the financial report**, consistent with the company's frugal approach to advancing production line upgrades. However, Cobra's production will improve production efficiency, and future higher sample output may be achieved with relatively small additional investment. **Conclusion**: Financial data does not directly reflect Cobra equipment costs (possibly smoothed by leasing), but the record of R&D asset impairment and depreciation suggests the process of old equipment elimination and new equipment deployment. Cobra's launch marks an important milestone in manufacturing capability ramp-up, and from an operational perspective, the company's manufacturing efficiency has greatly improved, and its effects are expected to be reflected in subsequent quarters' sample output and cost structure.

**Cooperation with Volkswagen PowerCo and Capacity Planning Expenditure**: QuantumScape's cooperation relationship with Volkswagen Group has undergone several changes, profoundly affecting financial strategy. Initially, the two parties established a joint venture (JVA) to jointly promote the industrialization of solid-state batteries, and Volkswagen's non-controlling interests were also reflected in the consolidated financial statements. However, in July 2024, QuantumScape signed a **cooperation agreement (PowerCo Collaboration Agreement)** with Volkswagen's battery subsidiary PowerCo, replacing the original joint venture model. According to the agreement, the goal of both parties is to industrialize QuantumScape's QSE-5 battery technology and plan to sign an **IP license agreement** after completing specific technical milestones. The license agreement will authorize PowerCo to use QSE-5 technology to produce batteries in one or more of its factories and require PowerCo to prepay an initial license fee of $130 million to QuantumScape. **This model change has two major financial impacts**: (1) QuantumScape may obtain considerable license income in the future (the first $130M), improving the zero revenue situation; (2) More importantly, the company no longer needs to directly invest huge amounts to build large-scale mass production factories, and the required capacity investment is mainly undertaken by PowerCo. QuantumScape clearly pointed out in the Q3 2024 financial report: compared to joint venture factory construction, the authorization model will reduce company revenue but **also significantly reduce cost and capital expenditure demand**. Financial data has already verified this point—fixed assets and CapEx did not show the originally expected huge growth in 2024, and cash consumption also decreased. At the same time, the company transferred technology to PowerCo through a cooperative team to support its customized mass production battery cells according to Volkswagen's needs. QuantumScape's responsibilities are more focused on technology development and trial production verification, so R&D expenses continue to remain high, without the inventory accumulation or construction in progress surge common during capacity expansion periods. It should be reminded that the authorization model is not without risks: if QuantumScape fails to achieve milestones as scheduled (such as **B sample battery cells being verified by automotive manufacturers**), PowerCo is not obligated to sign the final license, and the company will not receive this prepayment. But judging from the current progress, QuantumScape has successfully delivered B0 samples and started subsequent testing, and is expected to meet cooperation requirements. **Conclusion**: Financial data and disclosures fully reflect the authorization cooperation strategy—the company has significantly saved capital expenditure (production line investment slowed), reduced the debt ratio, while retaining enough cash to wait for potential license income. The expansion of the production line is more reflected in the partner's account, and QuantumScape's own financial report does not reflect large-scale capacity construction expenditure, which is highly consistent with its declared "light asset + technology authorization" business model.

**Sample Mass Production Preparation (Factory Investment and Raw Material Procurement Changes)**: Looking ahead to small-scale trial production of samples and future expanded production, it is necessary to consider the preparation of manufacturing facilities and supply chain. As of Q2 2025, QuantumScape is still in the B sample trial production stage, so **there has not been large-scale raw material procurement and inventory accumulation**. The financial report confirms this: accounts payable and prepayments, etc., have not shown significant growth, indicating that the company has not made large-scale raw material equipment reserves. On the contrary, material costs have slowly increased through the R&D item, indicating that procurement is mainly used for current trial production consumption. The company mentioned in risk factors that in the future, as commercialization advances, it will need to sign procurement agreements with suppliers, manage material delivery times and price fluctuations, etc. But these are still future challenges, and current financial data has not yet reflected large-scale supply chain activities. The acceleration of manufacturing activities is more reflected in **trial production efficiency**: with the introduction of the Cobra process and progress in multi-layer battery packaging technology, the company can increase output rate on existing facilities without immediately building new plants. Therefore, the construction in progress item has not seen significant growth (or is included in the small changes in the net value of fixed assets). **Conclusion**: QuantumScape has completed the construction and commissioning of a small-scale sample production line and accelerated through process innovation, improving sample delivery capability without significantly increasing asset investment. Financial data does not show the inventory and procurement surge related to large-scale production, indicating that the company's mass production preparation work is more focused on engineering technology integration, and real production expansion expenditure may gradually appear after obtaining customer orders and entering the C sample stage.

## Matching Conclusion of Financial Indicators and Manufacturing Expansion

In summary, QuantumScape's financial data over the past eight quarters generally **supports its declared technological advancement and trial production line ramp-up**, but also reflects the changes in investment pace brought about by the company's strategy adjustment:

**Acceleration of Manufacturing Activities**: Reflected in the internal structure of R&D expenses—depreciation and material costs increase, indicating more equipment is online and more battery samples are produced. The successful delivery of B sample battery cells proves that R&D investment has indeed produced support. The continuous investment in operating cash flow and personnel expansion also shows that the company has been intensifying R&D and trial production. These all confirm that manufacturing capability is gradually ramping up.

**Financial Support for Production Line Expansion**: Although there has been no surge in capital expenditure, QuantumScape has introduced advanced production line equipment (such as Cobra) through financing leases and reduced the pressure of self-building factories through authorization cooperation models. Therefore, the financial report does not show traditional "large-scale factory construction" expenditure, but from the changes in R&D expenses and fixed asset composition, the capital investment in production line upgrades can be seen (the signs of old equipment scrapping and new equipment investment are obvious). It can be said that **what the financial data reveals is "effective investment"**: achieving capacity improvement through technological upgrades with limited additional capital. This is consistent with the company's commitment to shareholders, i.e., prudent management of funds, "burning money" pace is controllable.

**Matching of Revenue and Inventory**: As of Q2 2025, QuantumScape is still on the eve of commercialization, with no product sales revenue, which is expected. Correspondingly, there is no inventory backlog—all output is for testing and improvement. This is consistent with the long cycle characteristics of solid-state battery commercialization. Before obtaining PowerCo license fees or other customer orders, **no revenue does not mean no progress**, but rather a necessary process for technology verification. Financial data such as high cumulative losses (cumulative losses of $350 million as of Q1 2025) also emphasize this point: the company has been investing, and future revenue will only appear after the product matures.

**Impact of Strategic Adjustment**: The strategy of authorization rather than joint venture factory construction has allowed QuantumScape to avoid huge capital expenditure, and its financial health has therefore remained stable (cash still exceeds $800 million, debt is extremely low). Although this makes **the financial report not show the capacity expansion expenditure of traditional manufacturing enterprises**, it precisely shows that QuantumScape has advanced manufacturing capability in a more capital-efficient way. Sufficient funds and slowed expenditure mean that the company has the capacity to continue ramping up production according to plan without worrying about short-term cash flow interruptions.

Overall, QuantumScape's financial reports over the past eight quarters **are basically consistent with its production line and technological progress**: a large amount of funds spent on R&D and trial production supports the technological leap from A sample to B sample; at the same time, the company prudently manages capital expenditure, achieves capacity improvement through innovative processes and cooperation models without blindly expanding the balance sheet. Although no revenue has been generated yet, this "invest first, then produce" model is financially sustainable, and cash reserves are sufficient to support the acceleration of manufacturing in the coming quarters. If B sample verification is successful and a license agreement is signed in the future, we can expect to see the first technology authorization revenue and possibly small-scale trial production sales revenue in the financial report, marking QuantumScape's official transition from R&D to commercialization. Current data indicates that the company has laid a solid financial and capacity foundation, waiting for technology maturity to be transformed into commercial results.

\*\* Source: \*\*QuantumScape's various 10-Q and 10-K financial reports, analyst conference call minutes, and company press releases. These materials collectively corroborate the correlation and evolution trajectory of QuantumScape's financial data with its manufacturing plans.

### 相關股票

- [QuantumScape (QS.US)](https://longbridge.com/zh-HK/quote/QS.US.md)